Market niche Target mid-sized biotech and diagnostic labs in autoimmune and infectious disease testing, leveraging AESKU.GROUP's focus on in vitro diagnostics and quantitative SARS-CoV-2 antibody tests to expand penetration beyond large incumbents.

Quality & speed Emphasize faster, more efficient, and reliable test systems as value props to clinics and hospitals seeking improved diagnostic outcomes and workflow efficiency, highlighting AESKU.DIAGNOSTICS offerings.

Digital enablement Leverage the AESQC portal and digital QC/IFA tools to upsell ongoing quality assurance services, training, and remote support agreements with diagnostic labs seeking regulatory and accreditation readiness.

Strategic partnerships Position AESKU.GROUP as a collaborator for multi-site institutions and academic labs by offering scalable diagnostic solutions, integration with existing IT stacks (SAP, WordPress/Joomla platforms), and co-development opportunities.

Global expansion Highlight potential for regional expansion and channel partnerships in markets with growing demand for autoimmune and infectious disease diagnostics, using a proven track record of launching new tests like quantitative SARS-CoV-2 antibodies to attract distributors and OEM opportunities.